Acadian Asset Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Acadian Asset Management’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-166	Closed	-$2K	–	1701
2017 Q1	$2K	Sell	166 -184	-53%	-$1.96K	﹤0.01%	1522
2016 Q4	$4K	Hold	350	–	–	﹤0.01%	1541
2016 Q3	$4K	Hold	350	–	–	﹤0.01%	1346
2016 Q2	$4K	Hold	350	–	–	﹤0.01%	1329
2016 Q1	$6K	Hold	350	–	–	﹤0.01%	1251
2015 Q4	$10K	Buy	350 +18	+5%	+$499	﹤0.01%	1243
2015 Q3	$9K	Sell	332 -21,229	-98%	-$781K	﹤0.01%	1149
2015 Q2	$774K	Buy	+21,561	New	+$672K	﹤0.01%	730
2014 Q2	–	Sell	-526	Closed	-$11K	–	1070
2014 Q1	$11K	Sell	526 -51,509	-99%	-$1.02M	﹤0.01%	917
2013 Q4	$670K	Buy	52,035 +24,222	+87%	+$336K	﹤0.01%	637
2013 Q3	$324K	Buy	+27,813	New	+$228K	﹤0.01%	696

Other funds holding INSY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

FHAM

Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acadian Asset Management's INSY Position: Q2 2017 in Review

Acadian Asset Management sold out of Insys Therapeutics, Inc. (INSY) in Q2 2017, closing a stake of 166 shares — an estimated $2K sold.

Acadian Asset Management first reported a position in INSY in Q3 2013 and held it in 11 quarters. The position peaked at $774K in Q2 2015. 118 funds tracked by Wall St. Rank hold INSY as of Q2 2017.

Acadian Asset Management reported no remaining Insys Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
Acadian Asset Management sold 166 Insys Therapeutics, Inc. shares in Q2 2017, an estimated $2K.
Acadian Asset Management first reported a position in Insys Therapeutics, Inc. in Q3 2013 and held it in 11 quarters.
Acadian Asset Management's Insys Therapeutics, Inc. position peaked at $774K in Q2 2015.
118 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2017.

Based on Acadian Asset Management's 13F filing for Q2 2017, filed 25 Jul 2017.